Novartis Story

NVS -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Macroaxis News
  
By Vlad Skutelnik
This post is geared to all Novartis management as well as to investors considering exiting their position in the enterprise. I will evaluate if Novartis shares are sensibly priced going into June and whether management should be worried. In defiance of conflicting performance in the last few months, the Stock's forward-looking signals remain relatively invariable which may send shares a bit higher in June 2019. The latest agitation may also be a sign of long running up-swing for the enterprise management. We found thirty-six available fundamentals for Novartis which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Novartis AG fundamentals including its Cash Flow from Operations, and the relationship between Cash and Equivalents and Market Capitalization . Given that Novartis AG has Price to Earning of 15.53X, we recommend you check Novartis last-minute market performance to make sure the company can sustain itself down the road. Use Novartis to enhance returns of your portfolios. The stock experiences normal upward fluctuation. Check odds of Novartis to be traded at $85.97 in 30 days.
Does Novartis have anything left for June?

The company has 30.59B in debt with debt to equity (D/E) ratio of 64.6 . This implies that the stock may be unable to create cash to meet all of its financial commitments. Novartis AG has Current Ratio of 0.91 suggesting that it has not enough short term capital to pay financial commitments when the payables are due. This firm dividends can provide a clue to current valuation of the stock. Novartis one year expected dividend income is about $4.6 per share. The company has Net Profit Margin of 23.11 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 30.11 % which entails that for every 100 dollars of revenue it generated 0.3 of operating income.


The entity has beta of 0.67. As returns on market increase, Novartis returns are expected to increase less than the market. However during bear market, the loss on holding Novartis will be expected to be smaller as well. The recent decline in stock price may encourage investors to take a closer look at the firm as it closed today at a share price of 81.05 on 2047050.000 in trading volume. The company directors and management have failed to build on market volatilities in April. However, diversifying your overall positions with Novartis may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.5287. The current volatility is consistent with the ongoing market swings in April 2019 as well as with Novartis AG unsystematic, company specific events. Novartis preserves 11.69% of shares owned by institutions. Novartis is trading at 81.88 which is 0.36% increase. Today lowest is 81.05. Novartis Average Assets is increasing over the last 5 years. Also, Novartis Earnings per Basic Share USD is increasing over the last 5 years. The latest value of Novartis Earnings per Basic Share USD is 5.01.

 2013 2014 2016 2018 2019 (projected)
Novartis Cost of Revenue 16,579,000,000  17,345,000,000  17,404,000,000  15,663,600,000  13,307,289,474 
Novartis Consolidated Income 9,292,000,000  10,280,000,000  17,794,000,000  16,014,600,000  12,028,631,579 

To conclude, our actual buy/sell recommendation on the enterprise is Hold. Novartis is currently undervalued with low probability of financial unrest for the next two years.

Novartis Revenue

About Contributor

Vlad Skutelnik
   Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Novartis AG. Please refer to our Terms of Use for any information regarding our disclosure principles.

Story Momentum

This article from Macroaxis published on the 16th of May 2019 contributed to the next trading period price escalation.The trading delta at closing time to the next next day price was 0.30% . The trading delta at closing time when the story was published to current price is 6.20% .

Similar stores for Novartis

few hours ago at finance.yahoo.com 
Sanofi to Buy U.S. Biotech Firm for 2.5 Billion in Cancer Push - Yahoo Finance
news
Sanofi to Buy U.S. Biotech Firm for 2.5 Billion in Cancer Push Yahoo Finance
few days ago at marketseat.info 
Where Novartis AG stock is Moving Now Spotted at 91.43 - Market Seat
news
Where Novartis AG stock is Moving Now Spotted at 91.43 Market Seat
over a week ago at www.surveydone.info 
Overview of Active Stocks Novartis AG - Stock Trends on Market
news
Overview of Active Stocks Novartis AG Stock Trends on Market
over two weeks ago at www.bloomberg.com 
Novartis to Pay 9.7 Billion in Latest Bet on New Technology - Bloomberg
bloomberg News
Novartis to Pay 9.7 Billion in Latest Bet on New Technology BloombergNovartis to Buy Cholesterol-Drugmaker Medicines Co. The Wall Street JournalNovartis Bets Big on Cholesterol Drug With 9.7 Billion Buyout of Medicines Co. FortuneNovartis to buy U.S. biotech The Medicines Co. for 9.7 bln NasdaqNovartis Reaches 9.7 Billion Deal to Buy Cholesterol Drugmaker Medicines Co. TheStreet.comView full coverage on Google News
over two weeks ago at www.thestreet.com 
Medicines Co. Surges After Cholesterol Drug Maker Linked to Novartis Takeover - TheStreet.com
Thestreet News
Medicines Co. Surges After Cholesterol Drug Maker Linked to Novartis Takeover TheStreet.com
over three weeks ago at financerecorder.com 
As Novartis AG Stock Value Rose, Chevy Chase Trust Holdings INC Upped Position - FinanceRecorder
news
As Novartis AG Stock Value Rose, Chevy Chase Trust Holdings INC Upped Position FinanceRecorder
over three weeks ago at www.nasdaq.com 
Amneal Pharma Recalls Certain Ranitidine Tablets - Nasdaq
nasdaq News
Amneal Pharma Recalls Certain Ranitidine Tablets Nasdaq
over a month ago at financemercury.com 
Citizens Northern Holds Position in Comcast Class A Novartis A G Holding Has Upped by Scharf Investments Llc -...
news
Citizens Northern Holds Position in Comcast Class A Novartis A G Holding Has Upped by Scharf Investments Llc FinanceMercury
over a month ago at mesaweekly.com 
Gilead Sciences Holder Grandfield Dodd Has Boosted Its Position by 557038 as Stock Rose Boston Common Asset Ma...
news
Gilead Sciences Holder Grandfield Dodd Has Boosted Its Position by 557038 as Stock Rose Boston Common Asset Management Trimmed Novartis A G Sponsored Adr Stake by 2.12 Million MS Wkly
over a month ago at mesaweekly.com 
As Texas Instrs Stock Rose, Holder Legacy Private Trust Has Cut Its Position Novartis A G Holder Welch Forbes ...
news
As Texas Instrs Stock Rose, Holder Legacy Private Trust Has Cut Its Position Novartis A G Holder Welch Forbes Decreased Its Stake by 738283 MS Wkly
over a month ago at www.twst.com 
Novartis AG 2019 Q3 results - Interim financial report - The Wall Street Transcript
Twst News
Novartis AG 2019 Q3 results - Interim financial report The Wall Street Transcript
over three months ago at www.nasdaq.com 
Pharma Stock Roundup JNJs Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs - Nasdaq
nasdaq News
Pharma Stock Roundup JNJs Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs NasdaqThis week, JJ JNJ received an unfavorable ruling in the litigation related to abuse of its opioid-based drugs. The FDA granted approval to Lillys LLY psoriasis ...
over three months ago at stocksbeat.com 
Charles Schwab Investment Advisory Has Boosted Its Novartis A G Holding by 6.38 Million Amazon Com Shareholder...
news
Charles Schwab Investment Advisory Has Boosted Its Novartis A G Holding by 6.38 Million Amazon Com Shareholder EG Advisors LP Raised Stake by 372020 as Market Value Rose Stocks BeatCharles Schwab Investment Advisory Inc increased its stake in Novartis A G by 1.64 percent based on its latest 2019Q1 regulatory filing with the SEC. Charles ...

Compare Novartis

Compare Novartis To Peers

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

  Probability Of Bankruptcy 
      Novartis Comparables 
Novartis is regarded fifth in probability of bankruptcy category among related companies. For stocks, Probability Of Bankruptcy is normalized value of Z-Score. For funds and ETFs it is derived from a multi-factor model developed by Macroaxis. The score is used to predict probability of a firm or a fund experiencing financial distress within next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100 indicating the actual probability the firm will be distressed in the next 2 fiscal years.
Please see also Novartis Hype Analysis, Novartis Correlation and Novartis Performance. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Search macroaxis.com